课题基金 / 基金详情

Immune-Shielded, Ultrasound-Stimulated Contrast Agents for Molecular Imaging

Immune-Shielded, Ultrasound-Stimulated Contrast Agents for Molecular Imaging
用于分子成像的免疫屏蔽、超声刺激造影剂
批准号:
7565682
负责人:
Mark Andrew Borden
金额:
$37.16万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2012-06-30

项目摘要

项目成果

Mark Andrew Borden的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Many promising studies indicate that molecular imaging with ultrasound can rapidly and economically provide sensitive, high-resolution detection of vascular events, such as angiogenesis, inflammation and thrombus. Thus, Ultrasound molecular imaging has the potential to have a widespread impact in clinical medicine and biological research. Current non-contrast-assisted ultrasound lacks the specificity to detect molecular signatures of targeted disease events, such as angiogenesis. However, ultrasound has the advantages of low cost, portability, and dynamic imaging capability, and is already widely used for clinical diagnosis. Targeted contrast agents have been developed for ultrasound molecular imaging, but their immunogenic properties make them untranslatable to the clinic. Thus, improving the safety and enhancing the sensitivity of ultrasound molecular imaging will have a significant impact on the diagnosis and assessment of thrombus, inflammation, and cancer. Before ultrasound molecular imaging can be translated to the clinic, the immunogenic effects caused by the exposure of targeting ligands on the contrast agent surface must be reduced. We propose research studies to examine in detail the physicochemical mechanisms of immune response to ultrasound contrast agents, and we will use this data to design contrast agents which are shielded from this immune response. Simultaneously, we will study the ultrasound interaction with stealth agents that have been shown in preliminary data to be selectively activated by ultrasound radiation force. Collaboration with an ultrasound device manufacturer will allow the modification of a small-animal imaging system for specific optimization to work with the new stealth contrast agents for enhanced pre-clinical imaging. The end goal will be to develop safer ultrasound contrast agents which will also exhibit increased specificity and circulation time in-vivo, and to improve ultrasound scanner technology to take advantage of new, stealth contrast agents. PUBLIC HEALTH RELEVANCE: Ultrasound molecular imaging has the potential to have a widespread impact in clinical medicine and biological research. Before ultrasound molecular imaging can be translated to the clinic, the immunogenic effects caused by the exposure of targeting ligands on the contrast agent surface must be reduced. The project will develop safer targeted ultrasound contrast agents with decreased immunogenicity and increased specificity in vivo and improve ultrasound scanner technology to take advantage of the new contrast agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Endoskeletal nanodrops for x-ray acoustic dosimetry
  • 批准号:
    10429759
  • 项目类别:
  • 资助金额:
    $20.04万
  • 财政年份:
    2022
  • 负责人:
    Mark Andrew Borden
  • 依托单位:
Endoskeletal nanodrops for x-ray acoustic dosimetry
  • 批准号:
    10660977
  • 项目类别:
  • 资助金额:
    $16.74万
  • 财政年份:
    2022
  • 负责人:
    Mark Andrew Borden
  • 依托单位:
Peritoneal Oxygen Delivery For The Treatment Of Acute Respiratory Distress Syndrome
  • 批准号:
    10556430
  • 项目类别:
  • 资助金额:
    $65.2万
  • 财政年份:
    2020
  • 负责人:
    Mark Andrew Borden
  • 依托单位:
Microbubble Dose Optimization for Image-Guided Drug Delivery
  • 批准号:
    10190853
  • 项目类别:
  • 资助金额:
    $35.23万
  • 财政年份:
    2019
  • 负责人:
    Mark Andrew Borden
  • 依托单位:
海外基金